Recombinant Antibody Expression Services

Recombinant antibody expression enables the production of defined antibody sequences in controlled host systems, offering high reproducibility, batch consistency, and scalability compared to traditional methods. By expressing antibodies from known gene sequences—typically in mammalian cells such as HEK293 or CHO—researchers can obtain antibodies with consistent structure, controlled isotype formats, and appropriate post-translational modifications.

At AbTriva, we provide flexible recombinant antibody expression services to support projects ranging from sequence-to-protein production through to scale-up for functional studies. Our workflows are designed for researchers who require reliable expression of monoclonal antibodies, antibody fragments, or engineered formats, with options tailored to application needs and timelines.

Expression Platforms

We offer multiple expression systems depending on the antibody format, yield requirements, and downstream application.

Expression System	Best For	Key Advantages
HEK293 Transient Expression	Rapid small- to mid-scale production	Fast turnaround, suitable for screening and early-stage studies
CHO Transient Expression	Higher-yield expression with mammalian processing	Improved scalability, widely used for therapeutic candidates
Stable CHO Cell Line Development	Long-term, large-scale production	Consistent expression, suitable for repeated or high-volume needs
E. coli Expression (for fragments)	Antibody fragments (e.g., scFv, Fab)	Cost-effective, rapid expression (no glycosylation)

System selection depends on antibody format and intended use.

Mammalian systems are typically preferred for full-length IgG due to proper folding and glycosylation, while bacterial systems are suitable for certain engineered fragments.

Supported Antibody Formats

We support expression of a range of recombinant antibody formats:

• Full-length IgG (various species and subclasses)
• Fab and scFv fragments
• Single-domain antibodies (e.g., VHH)
• Fc-fusion proteins
• Bispecific or engineered antibody formats (upon request)

If you have sequence information available, we can proceed directly to expression. For projects without sequences, upstream antibody discovery services can be integrated.

Applications & Use Cases

Recombinant antibodies produced through our services are commonly used in:

• Western blot (WB)
• ELISA and immunoassay development
• Flow cytometry
• Immunohistochemistry (IHC)
• Functional assays (e.g., blocking or binding studies)
• Assay development and optimization

Application-specific validation is not performed by default for all assays.

Validation strategies can be defined based on your experimental requirements and incorporated into the workflow upon request.

Overview of the Workflow

Phase	Service	Description	Deliverables	Timeline
Sequence Verification	Hybridoma Cell Sequencing	Sequencing of antibody-producing cells to obtain variable region sequences	Antibody sequencing results	~1 week
Phase 1	Full Gene Synthesis & Expression Vector Construction	Target gene is synthesized and cloned into an expression vector.	Expression plasmid	1–2 weeks
Phase 2	Transformation	The constructed plasmid is introduced into host cells.	Transformed host cells	2–3 days
Phase 3	Small-Scale Expression & Testing	Transfection into host cells, followed by preliminary expression and validation of the target protein.	Expression and validation results	5–7 days
Phase 4	Scale-Up Culture & Purification	Large-scale culture and purification using resin to isolate the target protein.	Purified target protein	7–10 days

Typical total timeline (transient expression): ~3–5 weeks

Timelines may vary depending on expression system, antibody format, and yield requirements.

Expression Scale Options

We offer flexible production scales to support different research stages:

• Small scale (1–10 mg) – Screening and assay development
• Mid scale (10–100 mg) – Functional studies and optimization
• Large scale (100 mg–gram level) – Extended studies or preclinical work

Scale-up strategies are aligned with your project goals and expression system.

Quality & Validation

We implement quality control measures appropriate for recombinant antibody production.

Standard Quality Control

• Purity assessment (SDS-PAGE)
• Concentration determination
• Basic integrity analysis

Functional Validation (performed upon request)

• Binding validation (e.g., ELISA)
• Application-specific testing (e.g., WB, flow cytometry)

Optional Characterization

• Affinity measurement (SPR or BLI)
• Aggregation analysis (SEC-HPLC)
• Endotoxin testing

Validation scope is defined during project planning and adjusted based on experimental needs.

Why Researchers Choose AbTriva

• Flexible expression systems
  HEK293, CHO, and bacterial platforms available based on application needs
• Fast turnaround for transient expression
  Suitable for rapid screening and early-stage projects
• Scalable production options
  From milligram to gram-level output
• Sequence-to-protein workflow
  Efficient transition from antibody sequence to purified product
• Transparent project planning
  Clear timelines, deliverables, and communication throughout

We recognize that expression yield and performance can vary depending on sequence characteristics and format. Our team works to optimize expression conditions while providing realistic expectations.

Start Your Project

Whether you need rapid expression for screening or larger-scale production for downstream studies, we can help design a workflow aligned with your research goals.

• Submit antibody sequences for evaluation
• Consult with our scientists on expression system selection
• Request a quote based on format and scale

Typical response time: 1–2 business days

Contact us to discuss your recombinant antibody expression needs.